AtaiBeckley (ATAI) Proxy filing summary

Executive summary

• Entered into a definitive agreement for acquisition by Eli Lilly, aiming to combine pipelines and accelerate patient access to key programs such as BPL-003 and VLS-01.

• Transaction expected to close in Q3 2026, pending shareholder and regulatory approvals.

• Until closing, both companies will operate independently with no changes to daily operations or reporting lines.

• Communication emphasizes business continuity and ongoing commitment to customer and partner obligations.

Voting matters and shareholder proposals

• Shareholders will vote on the proposed merger agreement at a special meeting, with proxy materials to be filed and distributed.

• Stockholders are encouraged to review proxy materials and related documents for important information regarding the merger.

Board of directors and corporate governance

• Directors, executive officers, and certain employees may participate in the proxy solicitation process.

• Information on director and executive officer stock ownership and compensation is available in prior SEC filings.